Search results
FDA Approval of Alvotech/Teva Ustekinumab Biosimilar | JD Supra
JD Supra· 2 days agoOn April 16, Alvotech and Teva announced the FDA approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Johnson and Johnson’s STELERA® (ustekinumab). The product was approved as a subcutaneous ...
Reviva Pharmaceuticals (NASDAQ:RVPH) vs. Bristol-Myers Squibb (NYSE:BMY) Head to Head Survey
ETF DAILY NEWS· 6 hours agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both medical companies, but which is the better investment? We will compare the ...
What Are the Most Effective Psoriasis Therapy Options?
Verywell Health via Yahoo News· 1 day agoWith many treatment options for psoriasis, how do you know which ones are right for you? Here are...
More people exposed to Manhattan Project chemicals deserve compensation, advocates say
Fox News via Yahoo News· 8 hours agoMissouri Sen. Josh Hawley is pushing to expand payments to those exposed to Manhattan Project...
Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by J.W. Cole Advisors Inc.
ETF DAILY NEWS· 4 days agoJ.W. Cole Advisors Inc. boosted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 9.5% in the 4th quarter, Holdings Channel reports. The firm owned 31,831 shares of the biopharmaceutical ...
AbbVie (ABBV) to Release Quarterly Earnings on Friday
ETF DAILY NEWS· 7 hours agoAbbVie (NYSE:ABBV – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Friday, April 26th. Analysts expect the company to announce earnings of ...
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rating Reaffirmed by HC Wainwright
ETF DAILY NEWS· 8 hours agoMoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday ...
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant...
NBC 17 Raleigh· 7 days ago...who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen achieved sustained remission from week 12 through week 52 compared to 29 percent of patients receiving placebo with a 52-week steroid taper regimen1− The safety profile in GCA was generally consistent with...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against...
Morningstar· 4 days agoBragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ventyx Biosciences, Inc ...
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Zacks via Yahoo Finance· 2 days agoIn October 2023, the FDA approved Cosentyx for treating moderate-to-severe hidradenitis suppurativa...